Liquidity Injections Via Reverse Repo in China decreased to 84.70 CNY Billion on Friday July 11 from 90 in the previous day. This dataset provides - China Liquidity Injections Via Reverse Repo- actual values, historical data, forecast, chart, statistics, economic calendar and news.

Gli iniezioni di liquidità tramite MLF in Cina sono diminuite a 500 miliardi di CNY in aprile rispetto ai 600 miliardi di CNY di marzo 2025. Questa pagina include un grafico con dati storici sulle iniezioni di liquidità in Cina tramite MLF.

China Short-term Liquidity Operation(SLO): Funds Injected data was reported at 0.000 RMB mn in Mar 2025. This stayed constant from the previous number of 0.000 RMB mn for Feb 2025. China Short-term Liquidity Operation(SLO): Funds Injected data is updated monthly, averaging 0.000 RMB mn from Oct 2013 (Median) to Mar 2025, with 138 observations. The data reached an all-time high of 855,000.000 RMB mn in Dec 2014 and a record low of 0.000 RMB mn in Mar 2025. China Short-term Liquidity Operation(SLO): Funds Injected data remains active status in CEIC and is reported by The People's Bank of China. The data is categorized under China Premium Database’s Money and Banking – Table CN.KA: Open Market Operation.

China Open Market Operation: Funds Injected/Withdrawn in the Week data was reported at -404,200.000 RMB mn in 09 May 2025. This records a decrease from the previous number of 358,300.000 RMB mn for 02 May 2025. China Open Market Operation: Funds Injected/Withdrawn in the Week data is updated daily, averaging 0.000 RMB mn from Jan 2009 (Median) to 09 May 2025, with 854 observations. The data reached an all-time high of 1,966,000.000 RMB mn in 20 Jan 2023 and a record low of -2,423,000.000 RMB mn in 05 Jan 2024. China Open Market Operation: Funds Injected/Withdrawn in the Week data remains active status in CEIC and is reported by The People's Bank of China. The data is categorized under China Premium Database’s Money and Banking – Table CN.KA: Open Market Operation: Daily.

In 2023, China injection molding machines market reached a value of USD 4.48 billion, and it is projected to surge to USD 6.01 billion by 2030

China Open Market Operation: Funds Injected/Withdrawn in the Month data was reported at 320,800.000 RMB mn in 30 Apr 2025. This records an increase from the previous number of -362,200.000 RMB mn for 31 Mar 2025. China Open Market Operation: Funds Injected/Withdrawn in the Month data is updated daily, averaging 18,000.000 RMB mn from Jan 2009 (Median) to 30 Apr 2025, with 196 observations. The data reached an all-time high of 1,973,300.000 RMB mn in 31 Jan 2025 and a record low of -1,133,000.000 RMB mn in 29 Feb 2024. China Open Market Operation: Funds Injected/Withdrawn in the Month data remains active status in CEIC and is reported by The People's Bank of China. The data is categorized under China Premium Database’s Money and Banking – Table CN.KA: Open Market Operation: Daily.

China Open Market Operation: Funds Injected into Circulation in the Month: Reverse Repo Turnover data was reported at 1,059,100.000 RMB mn in 31 May 2025. This records a decrease from the previous number of 3,922,700.000 RMB mn for 30 Apr 2025. China Open Market Operation: Funds Injected into Circulation in the Month: Reverse Repo Turnover data is updated daily, averaging 800,000.000 RMB mn from Jan 2012 (Median) to 31 May 2025, with 161 observations. The data reached an all-time high of 7,823,000.000 RMB mn in 30 Nov 2023 and a record low of 0.000 RMB mn in 30 Apr 2020. China Open Market Operation: Funds Injected into Circulation in the Month: Reverse Repo Turnover data remains active status in CEIC and is reported by The People's Bank of China. The data is categorized under China Premium Database’s Money and Banking – Table CN.KA: Open Market Operation: Daily.

Learn about the projected growth of the injection-moulding machine market in China over the next decade. Market volume is expected to reach 102K units by 2035, with a value of $3.4B.

Reverse Repo Rate in China remained unchanged at 1.40 percent in June. This dataset provides - China Reverse Repo Rate- actual values, historical data, forecast, chart, statistics, economic calendar and news.

There has been a growing demand for facial injection procedures in China as more young consumers believe that a better appearance can boost their salaries. According to a market report released in 2022, hyaluronic acid was the most widespread facial injection procedure in China, representing ********** of all treatment courses. However, ** percent of the overall market revenue was generated by botulinum toxin injections. Collagen, botulinum toxin, particle and polymer fillers, and hyaluronic acid are the major facial injectables that are effective in reducing wrinkles and face lines, and skin rejuvenation.

This study presents the case of China’s Jiangsu Province. The spatial-temporal pattern evolution of different manufacturing sectors is discussed using spatial analysis technology (spatial autocorrelation and standard deviation ellipses). The Granger test is used to analyze the relationship between the change in the manufacturing industry spatial agglomeration and regional economic differences. The following conclusions are drawn: 1) The spatial agglomeration trend of most manufacturing sectors is weakening. Much of the manufacturing sector, like the rubber and plastic product industries, has been transferred from southern to northern Jiangsu. 2) From the scale, only a minority of these enterprises possess substantial registered capital. The capital injection scale of more manufacturing enterprises is insignificant. At the same time, manufacturing companies with substantial financial resources are increasingly inclined to choose less-concentrated areas when choosing new investment areas. 3) The reduction of regional economic differences is considered to be the Granger-cause for the decline of the spatial agglomeration degree of the manufacturing industry in Jiangsu Province. Analyzing the spatiotemporal pattern of the manufacturing industry in Jiangsu Province will provide specific policy reference values for the manufacturing industry and economic development of Jiangsu province. In addition, for companies of different sizes, the findings of this paper also provide valuable references on how they can choose suitable investment locations according to their size in the future.

China Money Supply: Funds Injected into/Withdrawn from Circulation data was reported at -206.400 RMB bn in Mar 2025. This records an increase from the previous number of -953.800 RMB bn for Feb 2025. China Money Supply: Funds Injected into/Withdrawn from Circulation data is updated monthly, averaging 35.654 RMB bn from Feb 2003 (Median) to Mar 2025, with 257 observations. The data reached an all-time high of 1,829.474 RMB bn in Jan 2017 and a record low of -1,487.092 RMB bn in Feb 2017. China Money Supply: Funds Injected into/Withdrawn from Circulation data remains active status in CEIC and is reported by The People's Bank of China. The data is categorized under China Premium Database’s Money and Banking – Table CN.KA: Money Supply.

Chinese Medicine Injection Sales Market Outlook

The Chinese Medicine Injection Sales Market is witnessing significant growth, with the market size expected to reach $XX billion by 2032, growing at a compound annual growth rate (CAGR) of X.X% from $XX billion in 2023. This impressive growth trajectory is driven by several factors, including the increasing global interest in alternative and complementary medicine, alongside the proven benefits of traditional Chinese medicine (TCM) in treating various health conditions. The increasing integration of TCM into modern healthcare systems and the growing acceptance of natural and herbal remedies are major factors contributing to the market's expansion. The demand is further bolstered by technological advancements in extraction and formulation techniques, which enhance the efficacy and safety of Chinese medicine injections.

One of the primary growth factors for the Chinese medicine injection market is the escalating demand for alternative medicine, driven by the global wellness trend. As people increasingly seek natural and holistic health solutions, the effectiveness of Chinese medicine injections in managing chronic conditions such as arthritis, cardiovascular diseases, and respiratory disorders has come to the forefront. These injections are perceived as safer alternatives to synthetic drugs, reducing side effects and offering a more sustainable health approach. Additionally, the growing elderly population worldwide, prone to chronic illnesses, finds TCM injections particularly appealing due to their minimal invasive nature and holistic benefits, further fueling market growth.

Another significant driver is the rising governmental support and favorable policies promoting traditional medicine. Various countries, especially China, have implemented initiatives and policies to standardize and promote the integration of TCM into national healthcare systems. This support not only boosts domestic production but also enhances export opportunities, thereby expanding the market's global footprint. Furthermore, collaborations between pharmaceutical companies and research institutions are on the rise, aiming to conduct extensive clinical trials and research to validate the therapeutic efficacy of Chinese medicine injections. These collaborations are pivotal in enhancing product credibility and acceptance in international markets.

Technological advancements in extraction and drug delivery methods have also played a crucial role in market growth. Innovations such as nanotechnology and biotechnological processes have improved the bioavailability and absorption of herbal compounds in TCM injections. These advancements have led to the development of more effective formulations with higher therapeutic value and reduced side effects. Moreover, the continuous efforts in research and development to improve the pharmacokinetics and pharmacodynamics of these injections are likely to open new avenues for their application in treating a broader range of diseases.

Traditional Chinese Medicine (TCM) has long been revered for its holistic approach to health and wellness, emphasizing the balance of body, mind, and spirit. This ancient practice, which includes techniques such as acupuncture, herbal medicine, and tai chi, has been integral to Chinese culture for thousands of years. In recent decades, TCM has gained international recognition for its potential to complement conventional medical treatments. The integration of TCM into modern healthcare systems, particularly through Chinese medicine injections, exemplifies a growing trend towards combining traditional wisdom with contemporary medical practices. This fusion not only enhances patient outcomes but also broadens the scope of available therapeutic options, making TCM an attractive choice for those seeking comprehensive health solutions.

Regionally, the Asia Pacific dominates the Chinese medicine injection market, attributed to the widespread acceptance and historical roots of TCM in the region. The market is further supported by a large patient base and the presence of numerous local manufacturers. However, North America and Europe are rapidly emerging as significant markets due to the growing awareness and acceptance of TCM therapies. These regions are experiencing an increasing number of collaborations and partnerships aimed at promoting and distributing Chinese medicine injections, thereby expanding their regional market shares. The Middle East and Africa, and Latin America, though currently smaller markets, show potential for growt

Chinese Medicine Injection Market Outlook

In 2023, the global Chinese Medicine Injection market size was estimated to be USD 5.1 billion, and it is projected to reach USD 9.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.8%. This robust market expansion is driven by several factors, including the increasing acceptance of traditional Chinese medicine (TCM) in both domestic and international healthcare systems, advancements in medical technology, and supportive government policies.

One of the key growth factors for the Chinese Medicine Injection market is the increasing global interest in alternative medicine and holistic health approaches. With a growing awareness of the side effects and limitations of conventional pharmaceuticals, patients and healthcare providers alike are seeking alternative treatments. Chinese medicine injections, known for their natural and potent ingredients derived from herbs, animals, and minerals, offer promising therapeutic benefits for various ailments, including chronic diseases. This shift in consumer preferences towards natural and integrative medicine is expected to bolster market growth.

Another significant driver is the technological advancements in the formulation and delivery of Chinese medicine injections. Innovations in extraction and purification techniques have enhanced the efficacy and safety of these injections, making them more acceptable to a broader patient base. Additionally, advancements in nanotechnology and biocompatible materials have improved the delivery mechanisms, ensuring better absorption and targeted action of the medicinal compounds. These technological strides are likely to fuel the market's expansion over the forecast period.

The supportive regulatory framework and government policies in favor of traditional medicine further contribute to the market's growth. Countries like China have been heavily promoting TCM through various initiatives, including the integration of TCM into the national healthcare system and substantial funding for TCM research and development. These initiatives not only enhance the credibility of TCM on the global stage but also encourage the development and commercialization of Chinese medicine injections, thereby driving market growth.

Jinggangmycin, a well-known antibiotic derived from Streptomyces, has been gaining attention in the field of Chinese medicine injections. This compound is primarily used in agriculture to combat fungal infections in crops, but its potential therapeutic applications in human medicine are being explored. Researchers are investigating its efficacy in treating certain bacterial infections and its role in enhancing the immune system. The integration of Jinggangmycin into Chinese medicine formulations could offer a novel approach to addressing antibiotic resistance, a growing concern in the medical community. As studies continue to unfold, the inclusion of such bioactive compounds in traditional medicine could pave the way for innovative treatment options, further strengthening the market's growth trajectory.

Regionally, the Asia Pacific region dominates the Chinese Medicine Injection market, driven by the deep-rooted cultural acceptance of traditional medicine in countries like China, Japan, and South Korea. North America and Europe are also emerging as significant markets due to increasing awareness and acceptance of alternative therapies. The growing immigrant population from Asia in these regions has played a pivotal role in promoting traditional medicine practices. Furthermore, collaborations between Western pharmaceutical companies and TCM enterprises are likely to facilitate the market's growth in these regions.

Product Type Analysis

The Chinese Medicine Injection market is segmented into Herbal Injections, Animal-Derived Injections, and Mineral Injections. Herbal injections, derived from plant-based ingredients, constitute the largest segment within this market. These injections have gained immense popularity due to their efficacy in treating a wide range of ailments and their relatively safer profile compared to synthetic drugs. With the increasing global inclination towards herbal and natural products, herbal injections are expected to witness substantial growth during the forecast period.

Animal-derived injections, though a smaller segment compared to herbal injections, hold significant therapeutic potential. These injections are traditionally used for

In 2019, the market size of botulinum toxin from registered channels reached almost **** billion yuan, showing a slowdown in market growth for the first time since 2015. Botulinum toxin can be used in cosmestic and medical procedures. By injecting botox in a cosmetic treatment, it can reduce the appearance of skin wrinkles.

Forecast: Import of Injection-Moulding Machines for Rubber or Plastic to China 2022 - 2026 Discover more data with ReportLinker!

Forecast: Import of Injection or Compression Types Moulds for Metals or Carbides to China 2024 - 2028 Discover more data with ReportLinker!

China Self-Injection Devices Market focuses on the development, production, and application of devices that allow patients to administer medications themselves safely and effectively.

The Chinese Medicine Injection market exhibits robust growth potential, driven by increasing demand for traditional medicine, coupled with advancements in pharmaceutical technology leading to improved efficacy and safety profiles. This market is projected to reach a substantial size, with a Compound Annual Growth Rate (CAGR) showcasing significant expansion over the forecast period (2025-2033). While precise figures are unavailable, considering the global market trends for similar pharmaceutical segments and the considerable domestic demand in China, a reasonable estimate for the 2025 market size would be in the range of $2-3 billion USD, based on reports of substantial growth in related sectors. This estimate considers factors such as government support for traditional medicine and increasing health consciousness among the Chinese population. The CAGR, while not explicitly provided, can be logically inferred to be within a range of 8-12% annually, considering similar pharmaceutical market growth rates in developing economies and government initiatives. Key players, such as Green Valley Pharma, Changbaishan Pharmaceutical, and others listed, are instrumental in shaping the market's trajectory through innovation and expansion strategies.
Growth is fueled by factors including rising chronic disease prevalence necessitating effective and accessible treatment options, increased government investment in research and development of traditional Chinese medicine (TCM), and a growing preference among consumers for natural and holistic healthcare approaches. However, challenges remain, including stringent regulatory approvals, concerns regarding standardization and quality control within TCM production, and the need for further clinical research to validate the efficacy of some injections. The market segmentation, though not detailed, likely involves various injection types based on therapeutic applications and target diseases. The regional distribution reflects China's vast and diverse geography, with higher concentration in economically developed regions and substantial opportunities in less developed areas. Further research and access to more specific data points would refine these estimations.

In 2024, the Hong Kong injection-moulding machine market decreased by -14.7% to $20M, falling for the second year in a row after two years of growth. Over the period under review, consumption, however, saw a relatively flat trend pattern. Injection-moulding machine consumption peaked at $26M in 2019; however, from 2020 to 2024, consumption failed to regain momentum.